本文關(guān)鍵詞： Hela細(xì)胞 細(xì)胞因子 Gardiquimod增殖 信號(hào)通路 周期蛋白　出處：《安徽醫(yī)科大學(xué)》2014年碩士論文　論文類型：學(xué)位論文

【摘要】：目的（1）探討TLR7在Hela細(xì)胞中的表達(dá)（2）TLR7信號(hào)通路激活后對(duì)Hela細(xì)胞相關(guān)細(xì)胞因子、增殖、細(xì)胞周期的影響。 方法（1）培養(yǎng)Hela細(xì)胞，采用熒光定量PCR（Real-time PCR）及Western Blot的方法分析TLR7在Hela細(xì)胞中的表達(dá),同時(shí)用正常人外周血單個(gè)核細(xì)胞（peripheral blood mononuclear cell, PBMC）作為陽(yáng)性對(duì)照。（2）Western-Blot分析Gardiquimod對(duì)Hela細(xì)胞絲裂原蛋白激活激酶-胞外信號(hào)調(diào)節(jié)激酶（MAPKs-ERK1/2）及磷脂酰肌醇激酶-絲氨酸/蘇氨酸激酶（PI3K-AKT）蛋白磷酸化水平的影響,以及MAPKs-ERK1/2特異性阻斷劑PD98059，PI3K-AKT特異性阻斷劑LY294002阻斷這兩個(gè)信號(hào)通路，其磷酸化蛋白水平的變化。（3）通過Real-time PCR分析不同時(shí)間點(diǎn)Gardiquimod對(duì)Hela細(xì)胞下游VEGF，TIMP1，MMP2，IL-6，IL-15表達(dá)變化的影響，并通過特異性的信號(hào)通路阻斷劑PD98059，LY294002分析下游的VEGF，TIMP1等表達(dá)的變化是否依賴上述MAPKs-ERK1/2及PI3K-AKT這兩條信號(hào)通路的蛋白磷酸化水平的變化（。4）使用不同濃度的TLR7激動(dòng)劑Gardiquimod經(jīng)過不同的時(shí)間刺激Hela細(xì)胞，采用MTT比色法分析其對(duì)Hela細(xì)胞增殖的影響。（5）流式細(xì)胞技術(shù)檢測(cè)Gardiquimod作用于Hela細(xì)胞后其細(xì)胞周期的變化。（6）Western-Blot分析Hela細(xì)胞中TLR7激活后,細(xì)胞周期蛋白B1（CyclinB1）及細(xì)胞周期蛋白E（CyclinE）表達(dá)的變化。 結(jié)果（1）Real-time PCR及Western-Blot結(jié)果顯示，與PBMC相比，TLR7在Hela細(xì)胞呈現(xiàn)組成性弱表達(dá)。（2）Western-Blot結(jié)果表明，Gardiquimod激活TLR7后可以顯著增加Hela細(xì)胞中ERK1/2和AKT的蛋白磷酸化水平，特異性的阻斷劑PD98059，LY294002研究顯示，Gardiquimod依賴MAPK-ERK1/2和PI3K-AKT途徑發(fā)揮其促進(jìn)Hela細(xì)胞增殖的作用。（3）Real-time PCR分析，Gardiquimod經(jīng)不同時(shí)間處理Hela細(xì)胞后，其下游VEGF,TIMP1，MMP2，IL-6，，IL-15的表達(dá)都有不同程度的增加，并用上述特異性的信號(hào)阻斷劑后，其下游VEGF等因子的表達(dá)呈現(xiàn)不同程度的降低。（4）MTT結(jié)果顯示，TLR7激動(dòng)劑Gardiquimod可促進(jìn)Hela細(xì)胞的增殖，且呈時(shí)間及劑量效應(yīng)。（5）流式細(xì)胞檢測(cè)結(jié)果表明，TLR7配體促進(jìn)Hela細(xì)胞的增殖。（6）Western-Blot結(jié)果顯示，Gardiquimod可上調(diào)Hela細(xì)胞中CyclinB1和CyclinE蛋白的表達(dá)。 結(jié)論Gardiquimod通過MAPKs-ERK1/2和PI3K-AKT信號(hào)通路誘導(dǎo)Hela細(xì)胞下游VEGF等因子的表達(dá)，并促進(jìn)Hela細(xì)胞增殖。促增殖作用可能通過增加CyclinB1,CyclinE蛋白的表達(dá)。
[Abstract]:Objective 1) to investigate the effect of TLR7 expression in Hela cells after activation of TLR7 signaling pathway on cytokines, proliferation and cell cycle of Hela cells. Methods 1) Hela cells were cultured. Fluorescence quantitative PCR(Real-time PCR and Western Blot were used to analyze the expression of TLR7 in Hela cells. Peripheral blood mononuclear cell was also used in normal human peripheral blood mononuclear cells. Western blot analysis of mitogen-activated kinase-extracellular signal-regulated kinase (ECK) in Hela cells by Gardiquimod as a positive control. Effects of MAPKs-ERK1 / 2) and phosphatidylinositol kinase-serine / threonine kinase (PI3K-AKT) on phosphorylation levels. The two signaling pathways were blocked by MAPKs-ERK1/2 specific blocker PD98059 and PI3K-AKT specific blocker LY294002. The changes of phosphorylated protein level in Hela cells were analyzed by Real-time PCR. The effect of MMP2 on the expression of IL-15 was observed and the downstream VEGF was analyzed by PD98059 and LY294002, a specific signal pathway blocker. Whether the changes in expression of TIMP1 et al depend on the changes in protein phosphorylation level of the two signaling pathways, MAPKs-ERK1/2 and PI3K-AKT, mentioned above? Different concentrations of TLR7 agonist Gardiquimod were used to stimulate Hela cells for different time. The effect of Gardiquimod on the proliferation of Hela cells was analyzed by MTT colorimetry. Flow cytometry (FCM) was used to detect the cell cycle changes of Hela cells treated with Gardiquimod. Western-Blot was used to detect the activation of TLR7 in Hela cells. The expression of cyclin B _ (1) and cyclin E (E). Results Real-time PCR and Western-Blot showed that compared with PBMC. The results of Western-Blot showed that TLR7 was constitutively weakly expressed in Hela cells. Gardiquimod activation of TLR7 could significantly increase the level of protein phosphorylation of ERK1/2 and AKT in Hela cells and the specific blocker PD98059. LY294002 study showed. Gardiquimod depends on the MAPK-ERK1/2 and PI3K-AKT pathway to play its role in promoting the proliferation of Hela cells. Real-time PCR analysis. After Gardiquimod was treated with Hela cells at different time, the expression of IL-6 IL-15 was increased in the downstream of Hela cells. After the above specific signal blockers, the expression of VEGF and other factors in the downstream of the cells decreased in varying degrees. TLR7 agonist Gardiquimod could promote the proliferation of Hela cells in a time-and dose-dependent manner. The results of Western-Blot showed that TLR7 ligand promoted the proliferation of Hela cells. Gardiquimod can up-regulate the expression of CyclinB1 and CyclinE in Hela cells. Conclusion Gardiquimod induces the expression of VEGF and other factors downstream of Hela cells through MAPKs-ERK1/2 and PI3K-AKT signaling pathway. The proliferation of Hela cells may be enhanced by increasing the expression of cyclin E protein.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R329.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 ;Role of Toll-like receptors in regulatory functions of T and B cells[J];Chinese Science Bulletin;2008年08期

2 王毅錚;張勇;王瑜;高宏生;趙化冰;崔自由;陳虹;;白藜蘆醇對(duì)UVB損傷HaCaT細(xì)胞保護(hù)作用的雙向電泳圖譜差異分析[J];衛(wèi)生研究;2011年05期

本文編號(hào)：1452750